Formamide compounds as therapeutic agents
AssigneeGlaxo Wellcome Inc.
InventorsRobert Carl Andrews, Marc Werner Andersen, Dulce Garrido Bubacz, Joseph Howing Chan, David John Cowan, Michael David Gaul, Daryl Lynn McDougald, David Lee Musso, Michael Howard Rabinowitz, Jennifer Badiang Stanford, Robert William Wiethe
Life of this patent
Estimating the term…
Abstract
A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.
Claims19
A compound of the formula
- where
- R1 is
- where
- A1 is alkylene, alkenylene, alkynylene, or a direct bond;
- A2 is O, S, SO, SO2, or a direct bond;
- A3 is alkyl, alkenyl, alknyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, aryl, or hydrogen;
- R2 is
- where
- D1 is
- or a direct bond,
- D2 is alkylene, alkenylene, alkynylene, or a direct bond,
- D3 is cycloalkylene, cycloalkenylene, heterocyclylene, arylene, hetereroarylene, or a direct bond,
- D4 is alkyl, aryl, heteroaryl, or hydrogen;
- R3 is hydrogen or lower alkyl;
- R4 is
- where
- E1 is alkylene, alkenylene, alkynylene, or a direct bond,
- E2 is S, O, SO, SO2, C(O)O, OC(O), NR7, C(O)NR7, NR7C(O), SO2NR7, or a direct bond, where R7 is as defined;
- E3 is alkylene, cycloalkylene, cycloalkenylene, arylene, heterocyclylene, heteroarylene, or a direct bond;
- E4 is
- E5 is lower alkyl or hydrogen;
- R5 is hydrogen or lower alkyl;
- R6 is
- where
- Z1 is heteroarylene or a direct bond;
- Z2 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, aryl, NR8R9, OR8, or hydrogen, where R8 and R9 are as defined;
- and
- R7, R8, and R9 are, independently, hydrogen, alkyl, alkynyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl;
- or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.
A compound of the formula:
- where
- R1 is methyl, trifluoromethyl, ethyl, phenylsulfanylmethyl, phenylsulfonylmethyl, thiophene-2-sulfanylmethyl, thiophene-2-sulfonylmethyl, isopropyl, 3-methyl-1-butyl, benzyloxymethyl, 2-benzyloxy-1-ethyl, benzyl, n-propyl, 3,3,3-trifluoro-1-propyl, or cyclopropyl;
- R2 is isobutyl, cyclohexylmethyl, 3-(2-furyl)-1-propyl, 3-(4-biphenyl)-1-propyl, 4-methylcyclohexylmethyl, cycloheptymethyl, cyclohexyl, 5-methylthiophene-2-methyl, 4-phenyl-1-butyl, 3-phenyl-1-propyl, or benzyl;
- R3 is hydrogen, methyl, or ethyl;
- R4 is 3-(nitroimino-amino)methylamino-1-propyl, 3-(nitroimino-amino)methyl-ethylamino-1-propyl, 3-(nitroimino-amino)methyl-methylamino-1-propyl, 3-(nitroimino-amino)methyl-isopropylamino-1-propyl, 2-(nitroimino-amino)methylamino-1-ethylaminocarbonylethyl, 2-(nitroimino-amino)methylamino-1-ethylaminocarbonylmethyl, 4-(nitroimino-amino)methylamino-1-butyl, or 4-(nitroimino-amino)methylamino-2-butyl;
- R5 is hydrogen, methyl, ethyl, or n-propyl;
- and
- R6 is hydrogen, methyl, 5-ethyl-2-thiazolyl, cyclopropyl, cyclobutyl, cycloheptyl, 2,2,2-trifluoroethyl, cyclopentyl, 3-cyclopenten-1-yl, 2-pyridyl, 1,3,4-thiadiazol-2-yl, or 2-thiazolyl.
A compound of the formula:
- where
- Ris methyl, isopropyl, benzyl, n-propyl, 3,3,3-trifluoro-1-propyl, or cyclopropyl;
- R2 is isobutyl, cyclohexylmethyl, 4-methylcyclohexylmethyl, 5-methylthiophene-2-methyl, 3-phenyl-1-propyl, or benzyl;
- R3 is hydrogen;
- R4 is 3-(nitroimino-amino)methylamino-1-propyl, or 4-(nitroimino-amino)methylamino-2-butyl;
- R5 is hydrogen;
- and
- R6 is hydrogen, methyl, or 2-thiazolyl.
A compound of the formula:
- where
- R1 is methyl, n-propyl, or 3,3,3-trifluoro-1-propyl;
- R2 is isobutyl, 3-phenyl-1-propyl, or benzyl;
- R3 is hydrogen;
- R4 is 3-(nitroimino-amino)methylamino-1-propyl;
- R5 is hydrogen;
- and
- R6 is hydrogen, methyl, or 2-thiazolyl.
Dependencies are inferred from the claim text.